NCT02888236View on ClinicalTrials.gov

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

PHASE2CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

June 20, 2017

Study Completion Date

July 6, 2017

Conditions

Psoriasis Vulgaris

Interventions

DRUG

LEO 32731

DRUG

LEO 32731 Placebo

Trial Locations (1)

10117

Charité Universitätsmedizin Berlin, Dept. of Dermatology, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LEO Pharma

INDUSTRY